Invited Speaker: Dr Matthew Schrag,  MD, PhD, Vanderbilt School of Medicine, Nashville, Tennessee

Dr Matthew Schrag is a neurologist at Vanderbilt University Medical Center and runs the SchragLab at Vanderbilt, a neurobiology lab studying how the blood vessel network in the brain deteriorates in Alzheimer’s disease in a condition called cerebral amyloid angiopathy. His group studies post-mortem human brain tissue with advanced microscopy techniques to create detailed measurements of the vascular network associated cerebrovascular degeneration along with cell and molecular biology techniques to define mechanisms of Alzheimer’s disease that could lead to new approaches to treatment. The Schrag Lab’s work on the neuropathology of ARIA, a potentially dangerous side effect of anti-amyloid immunotherapies, contributed to the FDA’s decision to add a black box warning to the new drug Leqembi. Dr Schrag also works as an independent research integrity consultant and has brought to light a number of important instances of apparent research misconduct which likely had a significant impact on the field of Alzheimer’s research.

Title: Research integrity and the quest for a treatment for Alzheimer’s disease

Rigor and Reproducibility Seminar Series - UF Interdisciplinary T32 in Movement Disorders and Neurorestoration

This seminar series is jointly hosted by the UF Movement Disorders and Neurorestoration Program and the UF Health Science Center Libraries. Talks focus on rigor and reproducibility topics for the pre-doctoral training program.

This program and seminar series is funded by the National Institute of Neurological Disorders and Stroke (NINDS) through T32 NS082128, awarded to PIs Dawn Bowers (College of PHHP), Melissa Armstrong and David E. Vaillancourt (College of HHP).

The seminar will be recorded, with the recording distributed to registered attendees after the event.